Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 11 of 12
Feb 1, 2026Tenpoint Therapeutics' Yuvezzi eye drop represents a significant advancement in presbyopia treatment through its dual mechanism of action. This approval not only marks a pivotal milestone for the company but also impacts the competitive landscape of vision therapeutics. Supported by substantial financing, Yuvezzi is poised to reshape how presbyopia is managed clinically.
Sophia Reynolds
Jan 29, 2026Recent advancements in genetic research have deepened our understanding of human longevity. This article explores the findings of a pivotal study that redefines the impact of inherited genes on lifespan and discusses implications for aging research and therapeutic strategies.
TCB Team
Jan 28, 2026Phase 2 data reveal Roche's investigational GLP-1 and GIP agonist achieved a 22.5% placebo-adjusted weight loss at 48 weeks. This efficacy supports the advancement to pivotal Phase 3 trials, marking a critical step in the development of new obesity treatment options amid a highly competitive market.
TCB Team
Jan 27, 2026Emerging biotech Baseline Therapeutics is positioning itself as a challenger in the development of GLP-1–based therapies for alcohol use disorder. Their lead asset, BT-001, is set to enter late-stage clinical trials, marking a significant step in tackling addiction through novel mechanisms.
Daniel Cho
Jan 26, 2026Endometriosis is a painful condition affecting millions, frequently suffering from diagnostic delays due to complex symptoms and limited testing tools. Several biotech companies are now leveraging advances in diagnostics to develop new tests that promise to simplify and accelerate detection, potentially transforming patient outcomes and quality of life.
TCB Team
Jan 26, 2026Accelerating progress in rare disease therapeutics demands innovative strategies beyond traditional frameworks. A sandbox approach that combines robust data analytics with regulatory experimentation offers a promising pathway to address inherent complexities and drive advancement in this difficult field.
Sophia Reynolds
Jan 24, 2026In the competitive landscape of narcolepsy treatments, Alkermes is pursuing strategic research and development to not only advance its orexin receptor-targeting drug Alixorexton but also to pave the way for innovative fatigue therapies, potentially transforming patient care beyond sleep disorders.
Sophia Reynolds
Jan 20, 2026A recent study analyzing diabetes management outcomes has provided compelling evidence that bariatric surgery delivers better control of type 2 diabetes than GLP-1 medications irrespective of patients’ income levels. This insight carries significant implications for the approach to diabetes care and healthcare policy.
TCB Team
Jan 15, 2026In the face of significant financial challenges impacting biomedical research, new data reveal a surprising uptick in graduate student enrollment in biomedical degree programs across the United States. This trend underscores the resilience and continued interest in the biomedical field, reflecting a potential shift in future research dynamics despite economic headwinds.
TCB Team
Jan 10, 2026Aktis Oncology’s public offering is set to strengthen its position in the radiopharmaceutical sector. The company’s novel approach with miniprotein-based radioconjugates promises potential benefits over existing targeted radiation therapies. Additionally, Aktis has established a discovery partnership with Eli Lilly to enhance its pipeline.
TCB Team
Jan 9, 2026Illumina named former NIH genomics director Eric Green as its Chief Medical Officer. His appointment comes as the company continues to push boundaries in genomics technologies and applications. Green’s experience is expected to enhance clinical strategy and innovation at Illumina.
TCB Team
Jan 9, 2026Building on the pioneering work of Baby KJ, this startup leverages both scientific breakthroughs and new FDA regulatory programs to accelerate development of personalized gene therapies utilizing CRISPR technology.
TCB TeamMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.